AzTrials
AzTrials

Acute Calculous CholecystitisACMENCT04744441

Mortality Risk Estimation in Acute Calculous Cholecystitis: Beyond the Tokyo Guidelines

An observational study of Acute Calculous Cholecystitis, run by Hospital del Mar.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Acute calculous cholecystitis (ACC) is the second most frequent surgical condition in emergency departments, the complication rate of ACC is 20-55%, and the mortality rate is 0.5-15% in recent series. Read more about this study

Who is it for?
Any age
Conditions the study is for
Acute Calculous Cholecystitis
What is being tested?
CHOLECYSTECTOMY, PERCUTANEOUS CHOLECYSTOSTOMY and EXCLUSIVE ANTIBIOTICS
How many people
963 participants
Where
No sites listed yet
Study dates
Jan 2011to Mar 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: All patients admited with a diagnostic of Acute Cholecystitis in a dedicated surgical emergency unit, from January 2011 to December 2016, in a Metropolitan University Hospital in Barcelona, Spain.

Who may be able to join

  • All patients were selected if they had acute cholecystitis according to the Tokyo Guidelines of 2018 (TG18) and/or received a diagnosis of ACC in the Pathology report. The study case definition was a 'Pure Acute Cholecystitis.

Who cannot join

None listed.

About this study

Acute calculous cholecystitis (ACC) is the second most frequent surgical condition in emergency departments, the complication rate of ACC is 20-55%, and the mortality rate is 0.5-15% in recent series. The Tokyo Guidelines (TG) advocate for different initial treatments of ACC with no clear evidence that all patients will benefit from them.

The objective of the study is to identify the risk factors for mortality in ACC and compare them with TG classification.

Read more

It is a retrospective cohort study conducted from January 2011 to December 2016 in a single center with a dedicated surgical emergency unit in a Metropolitan University Hospital in Barcelona, Spain. The analysis of the data was finished in March 2020.

The study candidates comprised 963 consecutive patients with a diagnosis of ACC according to the TG18 and/or received a diagnosis of ACC in the Pathology report in those that an emergent cholecystectomy was performed.

The study case definition was a 'Pure Acute Cholecystitis' (pure ACC); therefore, patients with any other concomitant diagnosis potentially influencing outcome (Postoperative cholecystitis, Acute Cholangitis, Acute Pancreatitis, Incidental Cholecystectomy, Acalculous Cholecystitis, Chronic Cholecystitis/Persistent Colic, Post-endoscopic retrograde pancreato-cholangiography, or Neoplasia) were excluded from the final analysis.

Variables:

Primary data were available from a prospective database maintained in File Maker v.12 (Mountainview, CA, USA), which included basic demographic data, type of interventions, sex, days of admission, and complications. Every record was completed by browsing the electronic patient record, adding laboratory and microbiology data, as well as antibiotic therapy, duration of procedure, additional procedures, and grade of acute cholecystitis according to the TG18 diagnostic criteria.

Preoperative comorbidities were assessed using the Charlson Comorbidity Index and surgical risk by ASA classification. The type of initial treatment was classified as Surgical Treatment (Cholecystectomy either by laparoscopy or laparotomy) or Non-Surgical Treatment, which was either percutaneous cholecystostomy or intravenous antibiotics alone.

The main outcome measure was the mortality after the diagnostic of ACC. In the patients that were discharged, 30 days after the diagnosis, if the patients was not discharged in 30 days, at any time during the same admission.

Interventions:

All patients received intravenous antibiotic therapy from the moment the diagnosis was formulated, according to a fixed protocol.

Ultrasound-guided cholecystostomy was performed percutaneously with an 8-Fr catheter (SKATER ™, Argon Medical Devices, Rochester, NY, USA) by either transhepatic or transperitoneal insertion, at the discretion of the radiologist.

Laparoscopic Cholecystectomy was performed according to the French technique using 4 trochars. The content of the gallbladder was evacuated by Veress needle puncture when necessary.

Statistical Analysis:

The normal distribution of the quantitative variables was assessed using the Kolmogorov-Smirnov test, which showed that none of the variables were normally distributed; therefore, their values were expressed as median and interquartile ranges. The Mann-Whitney U non-parametric test was used to assess the significance of differences between means.

The association between qualitative variables was assessed with the chi-square test or Fisher's exact test, as required. The increased risk of an event associated with a variable was reported as the odds ratio (OR) and 95% confidence interval (CI).

As this was a retrospective observational study and the treatment groups were markedly asymmetric, we used the propensity score matching method to select and compare two subgroups of patients evenly balanced by severity according to the TG18 criteria and by comorbidity according to the Charlson Comorbidity Index.

A model for predicting mortality was built using binomial logistic regression with stepwise progressive conditional entry and standard baseline conditions for admission and rejection of variables with significant differences in the univariate analysis. The discrimination power of the model was assessed by receiver operating characteristic (ROC) curves and was compared with the DeLong method.

Legal and Ethical considerations This study was approved by the clinical research ethical committee of the Hospital del Mar and was classified as a non-clinical trial.

Being tested
CHOLECYSTECTOMY, PERCUTANEOUS CHOLECYSTOSTOMY, EXCLUSIVE ANTIBIOTICS
Keywords
Emergent Cholecystectomy, Mortality in acute Cholecystitis, High Risk Patient, Morbidity in Acute Cholecystitis, Risk Factors in Acute Cholecystitis, Unfit for Surgery, Acute Cholecystitis, Acute Calculous Cholecystitis
Medical subject headings
Cholecystitis, Acute

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CHOLECYSTECTOMYProcedure or surgery

    Also called Surgical Treatment

    Surgical treatment

  • PERCUTANEOUS CHOLECYSTOSTOMYProcedure or surgery

    Also called Non-Surgical Treatment

    Patients treated with a percutaneous cholecystostomy

  • EXCLUSIVE ANTIBIOTICSProcedure or surgery

    Also called Non-Surgical Treatment

    Patients that are treated only with i.v. antibiotics

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To describe the mortality in patients with a diagnostic of Acute Calculous Cholecystitis.

    The main outcome measure was the number of deaths after the diagnosis of Acute Calculous Cholecystitis.

    In the patients that were discharged: 30 days after the diagnosis. If the patients was not discharged in 30 days, at any time during the same admission.

    Measured: 2011-2016

  2. To describe the causes of death after a diagnostic of Acute Calculous Cholecystitis

    Every death after a diagnostic of Acute Calculous Cholecystitis was defined as: septic shock, heart failure, respiratory failure and/or complication of a concomitant chronic disease before the diagnostic of pure ACC.

    Measured: 2011-2016

Secondary outcomes (2)
  1. Study of the risk factors for mortality in patients with a diagnostic of Acute Calculous Cholecystitis

    The association between qualitative variables was assessed with the chi-square test or Fisher's exact test, as required. The increased risk of an event associated with a variable was reported as the odds ratio (OR) and 95% confidence interval (CI).

    • Demographic data (gender, age)
    • Physiological parameters (Temperature, blood pressure, cardiac and respiratory rates)
    • Laboratory test (Bilirubin, Creatinine, Alkaline phosphatase, Gamma-glutamyl-transpherase, Glutamil oxaloacetic transaminase, PT-INR, Lactate, WBC, Partial oxygen pressure, CRP and Platelets)
    • Type of intervention and additional procedures
    • Grade of severity of ACC following the TG18
    • Preoperative comorbidities were assessed using the Charlson Comorbidity Index and surgical risk by ASA classification.

    Measured: 2011-2016

  2. Comparison the mortality of surgical treatment vs. non-surgical treatment

    As this was a retrospective observational study and the treatment groups were markedly asymmetric, we performed a propensity score matching method to select patients with an equal morbidity according to the Charlson Comorbidity Index and TG18 Classification at the momento of the diagnostic of ACC. Then we classified the complications of each group following the Clavien-Dindo's Classification.

    Measured: 2011-2016

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Feb 2021
  2. Study startJan 2011
  3. Primary completionDec 2016
  4. Study completionMar 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
963 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04744441
Sponsor's protocol ID
Mortality Estimation in ACC
Acronym
ACME
Status last verified
Feb 2021
First submitted
25 Jan 2021
Last updated
9 Feb 2021
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: all primary and secondary variables of anonimyzed individual data set will be provided

Publications

  • Gonzalez-Castillo AM, Sancho-Insenser J, De Miguel-Palacio M, Morera-Casaponsa JR, Membrilla-Fernandez E, Pons-Fragero MJ, Pera-Roman M, Grande-Posa L. Mortality risk estimation in acute calculous cholecystitis: beyond the Tokyo Guidelines. World J Emerg Surg. 2021 May 11;16(1):24. doi: 10.1186/s13017-021-00368-x.

    PubMed 33975601

Questions about this trial

What is this clinical trial studying?

An observational study of Acute Calculous Cholecystitis, run by Hospital del Mar.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To describe the mortality in patients with a diagnostic of Acute Calculous Cholecystitis. (time frame: 2011-2016). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04744441, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Feb 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in